GANX

Gain Therapeutics, Inc. (GANX) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Gain Therapeutics is a clinical-stage biotechnology company developing small molecule therapeutics for central nervous system (CNS) disorders, lysosomal storage disorders, and metabolic diseases. The company's lead product candidate, GT-02287, is in Phase 1b clinical trials for the treatment of Parkinson's disease. The company operates as a single segment focused on research and development.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by $0.98 million to $5.35 million.
  • Research & Development (R&D): Increased by $0.51 million to $2.76 million, driven by costs for the GT-02287 Parkinson's program, higher personnel costs, and unfavorable foreign exchange rates (Swiss Franc and Australian Dollar strengthening).
  • General & Administrative (G&A): Increased by $0.48 million to $2.59 million, primarily due to higher professional fees, personnel costs, and foreign exchange impacts.
• Foreign Exchange: Net foreign exchange loss increased to $0.17 million from $0.10 million in the prior year due to currency fluctuations.
• Financing Activity: Net proceeds from financing activities decreased significantly to $0.40 million (vs. $2.40 million in Q1 2025), primarily due to reduced sales under the At-The-Market (ATM) program ($0.43 million in Q1 2026 vs. $2.42 million in Q1 2025).
• Equity: Issued 184,662 shares via the ATM program and 229,710 shares via warrant exercises during the quarter.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. With $16.5 million in cash, the company projects it will not have sufficient funds to operate for 12 months from the filing date. Additional capital is required to fund operations beyond the first quarter of 2027.
• Clinical Progress:
  • Phase 1b study for GT-02287: 19 patients completed Part 1; 16 elected to continue into the 9-month extension (Part 2). Full analysis of Part 1 is expected throughout 2026.
  • New data presented in March 2026 showed reductions in cerebrospinal fluid glucosylsphingosine and DOPA decarboxylase (DDC) levels in treated participants.
  • Preclinical data for a new GCase modulator, GT-04686, was unveiled, ready for IND-enabling studies.
• Capital Strategy: The company plans to raise additional capital through equity financings (including the ATM program), debt, grants, or strategic collaborations. Management is reviewing cost structures to optimize cash burn.
• Legal Proceedings: A lawsuit filed by Andrew Schwartzberg regarding warrant exercise prices was amended in April 2026, seeking over $3.1 million in damages. The company intends to vigorously defend the action.
• Subsequent Events: Between April 1 and May 8, 2026, the company sold 296,697 shares via the ATM program for net proceeds of $0.59 million.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash exhaustion and the status of any new financing discussions or agreements.
• ATM Program Capacity: Confirm the remaining capacity under the $50 million ATM program and the average selling price trends.
• Clinical Milestones: Monitor the release of the full Phase 1b Part 1 data analysis and the timeline for Part 2 completion (expected September 2026).
• Legal Exposure: Track the outcome of the Schwartzberg litigation and any potential accruals for damages.
• Foreign Exchange Impact: Assess the ongoing impact of the strengthening Swiss Franc and Australian Dollar on future operating expenses.